Ding Fang Chao Linda, Karkhaneh Mohammad, Zorzela Liliane, Jou Hsing, Vohra Sunita
Department of Pediatrics & Child Health, University of Manitoba, Winnipeg, Manitoba.
Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta.
Paediatr Child Health. 2019 Sep;24(6):383-394. doi: 10.1093/pch/pxz036. Epub 2019 May 4.
Functional abdominal pain disorders (FAPD) are prevalent in the paediatric population, however, there is currently no consensus regarding best practices for treatment. The use of probiotics is becoming popular to treat FAPD. The goal of this rapid review is to synthesize the best evidence on the use of probiotics in children with FAPD.
Searches were conducted on five main databases. Randomized controlled trials (RCTs) of probiotic use in children (0 to 18 years) with FAPD were searched. Populations of interest were patients with functional abdominal pain (FAP), irritable bowel syndrome (IBS), and functional dyspepsia (FD), recruited based on Rome criteria. Outcomes of interest were changes in abdominal pain severity, frequency, and duration.
Eleven RCTs with 829 participants with the diagnosis of FAP (n=400), IBS (n=329), FD (n=45), and mixed population (n=55) were included. Of six studies of children with FAP, two (n=103) used GG (LGG) and reported no significant effects on pain, and four (n=281) used DSM 17938, of which three (n=229) reported significant positive effects on either severity or frequency of pain. Of six trials of children with IBS, four (n=219) used LGG, of which three (n=168) reported a positive effect. One (n=48) used bifidobacteria and one used VSL #3 (n=59), both demonstrating positive effects with probiotics. Two studies of FD reported no benefit. No adverse events were attributed to probiotics.
There is preliminary evidence for use of probiotics, particularly LGG, in reducing abdominal pain in children with IBS. There are inconsistent positive effects of other probiotics, including DSM 17938, in reducing pain in patients with FAP, IBS, or FD. More RCTs with rigorous methodology using single or combination probiotics are warranted.
功能性腹痛障碍(FAPD)在儿科人群中很常见,然而,目前对于最佳治疗方法尚无共识。益生菌的使用在治疗FAPD方面正变得越来越普遍。本快速综述的目的是综合关于益生菌用于患有FAPD儿童的最佳证据。
在五个主要数据库中进行了检索。检索了益生菌用于0至18岁患有FAPD儿童的随机对照试验(RCT)。感兴趣的人群是根据罗马标准招募的功能性腹痛(FAP)、肠易激综合征(IBS)和功能性消化不良(FD)患者。感兴趣的结局是腹痛严重程度、频率和持续时间的变化。
纳入了11项RCT,共829名参与者,诊断包括FAP(n = 400)、IBS(n = 329)、FD(n = 45)和混合人群(n = 55)。在六项针对患有FAP儿童的研究中,两项(n = 103)使用了鼠李糖乳杆菌GG(LGG),报告对疼痛无显著影响,四项(n = 281)使用了DSM 17938,其中三项(n = 229)报告对疼痛严重程度或频率有显著积极影响。在六项针对患有IBS儿童的试验中,四项(n = 219)使用了LGG,其中三项(n = 168)报告有积极效果。一项(n = 48)使用了双歧杆菌,一项使用了VSL#3(n = 59),两者均显示益生菌有积极效果。两项关于FD的研究报告无益处。没有不良事件归因于益生菌。
有初步证据表明使用益生菌,特别是LGG,可减轻患有IBS儿童 的腹痛。其他益生菌,包括DSM 17938,在减轻FAP、IBS或FD患者疼痛方面的积极效果并不一致。需要更多采用严谨方法使用单一或联合益生菌的RCT。